The effect of melatonin and N-acetylcysteine on the state of the orientation research activity in rats under conditions of the experimental diabetes mellitus




diabetes mellitus, diabetic neuropathy, streptotrozotocin, melatonin, N-acetylcysteine, "open field", "dark-light camera"


An important task of modern medicine is the search and development of drugs that exhibit cerebroprotective properties in patients with type 1 diabetes mellitus.

Aim. To study the effects of melatonin and N-acetylcysteine on the orientation research activity and anxiety of rats under conditions of the experimental diabetes mellitus.

Materials and methods. Rats with induced diabetes mellitus received N-acetylcysteine (1.5 g/kg), melatonin (10 mg/kg), or their combination for 5 weeks. The “open field” test and “dark-light chamber” were used to study the orientation research activity and anxiety of rats.

Results. The introduction of N-acetylcysteine, melatonin, and their combination contributed to an increase in the orientation research activity and a decrease of anxiety in rats with the experimental diabetes mellitus. In animals received pharmacotherapy the horizontal and vertical activity increased, the number acts of defecation and urination decreased in the “open field” test. The time of staying in the dark compartment of the chamber reduced, while the time of staying in the light compartment increased, animals moved and peeped out more often in the “dark-light chamber” test.

Conclusions. N-acetylcysteine and melatonin in monotherapy and in combination improve glycemic control and the body weight of rats with the experimental type 1 diabetes mellitus, have a positive effect on the emotional (reduce the anxiety) and vegetative status, preventing disorders of the locomotor and orientation research activity.

Author Biographies

O. A. Fitsner, Bogomolets National Medical University

Postgraduate student, Department of Clinical Pharmacology and Clinical Pharmacy

M. V. Khaitovych, Bogomolets National Medical University

MD, Professor, Head of Department, Department of Clinical Pharmacology and Clinical Pharmacy

I. M. Ryzhko, Bogomolets National Medical Universit

Head of Laboratory of Clinical Laboratory Diagnostics in Scientific Research Institute of Experimental and Clinical Medicine

L. I. Holopykho, Bogomolets National Medical University

Candidate of Medicine (Ph.D.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy


Zelinska, N. B., Hloba, Ye. V., Pohadaieva, N. L. (2013). Klinichna endokrynolohiia ta endokrynna khirurhiia, 1, 80–83.

Hamed, S. A. (2017). Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert Rev Clin

Pharmacol. Available at:

Prasad, S., Sajja, R. K., Naik, P., Cucullo, L. (2014). Diabetes Mellitus and Blood–Brain Barrier Dysfunction: An Overview. J

Pharmacovigil. Available at:

Klypa, T. V., Orekhova, M. S., Zabrosaeva, L. I. (2015). Sakharnyi diabet, 4, 33–41.

Bensaoula, D. A., Boukhris, N., Tahraoui, A. (2016). Hesperidin effects on behavior and locomotor activity of diabetic Wistar

rat. African Journal of Biotechnology, 15 (45), 2572–2577. doi: 10.5897/ajb2016.15715

Moghadami, M., Moghimi, A., Ahangar, E. (2012). Effects of Infantile Repeated Hyperglycemia on Behavioral Alterations in Adult Male and Female Rats. Neur science, 4, 60–67.

Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes (2010). Official Journal of the European Communities, 276, 33–79.

Stefanov, O. V. (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena, 528.

Tukalenko, Ye. V., Tubaltseva, I. I., Dmytriieva, I. R. et al. (2016). Naukovi pratsi. Tekhnohenna bezpeka. Radiobiolohiia, 268, 99–104.

Shastun, N. P., Opryshko, V. I. (2015). Zdobutky klinichnoi i eksperymentalnoi medytsyny, 4, 72–75.

Tatem, K. S., Quinn, J. L., Phadke, A. et al. (2014). Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring

System for Skeletal Muscle Diseases. J Vis Exp. Available at:

Wang, J.–Q., Yin, J., Song, Y.–F. et al. (2014). Brain Aging and AD–Like Pathology in Streptozotocin–Induced Diabetic Rats. Journal of Diabetes Research. Available at:

Zhang, W. J., Tan, Y. F., Yue, J. T. et al. (2008). Impairment of hippocampal neurogenesis in streptozotocin–treated diabetic rats. Acta Neurol Scand. Available at: ttps://

Smirnov, A. V., Shmidt, M. V., Panshin, N. H., Kuznetcova, V. A. (2016). Volgohradskii nauchno–medycsynskii zhurnal, 2, 37–39.

Shvedskyi, V. V., Khodakivskyi, O. A. (2012). Bukovynskyi medychnyi visnyk, 1, 150–156.

Park, D. J., Koh, P. O. (2018). Diabetes aggravates decreases in hippocalcin and parvalbumin expression in focal cerebral ischemia. Neurosci Lett. Available at: ttps://

Cunnane, S, Nugent, S, Roy, M et al. (2011). Brain fuel metabolism, aging, and Alzheimers disease. Nutrition. Available at:

Cholerton, B., Baker, L. D. (2011). Insulin resistance and pathological brain ageing. Diabet Med. Available at:





Pre-clinical studies of new drugs